Biotech

Nanollose Limited (ASX:NC6) Annual Report

🕔8/26/2022 8:58:47 AM

The period marked a transformational year for Nanollose Limited (ASX:NC6) (FRA:N0L), underpinned by a series of critical R&D breakthroughs.

Read Full Article

Apiam Animal Health Limited (ASX:AHX) FY22 Reporting Date and Investor Webinar Notification

🕔8/22/2022 9:50:19 AM

Apiam Animal Health Limited (ASX:AHX) will release its financial results for the twelve months ended 30 June 2022 on Monday August 29 2022.

Read Full Article

Nanollose Limited (ASX:NC6) Codi Group Cooperation Agreement Extended

🕔8/18/2022 9:36:47 AM

Nanollose Limited (ASX:NC6) (FRA:N0L) is pleased to advise that it has extended its Cooperation Agreement with Codi International BV, part of the Codi Group ("Codi"), for a further three years.

Read Full Article

Apiam Animal Health Limited (ASX:AHX) Expands Commitment to Racing Industry with Naming Sponsorship of Bendigo Racecourse

🕔8/1/2022 12:53:58 PM

Within racing circles, Bendigo Racecourse is commonly referred to as the Nursery of Champions due to the amount of legends that have started their careers at the famous track now named Apiam Bendigo racecourse.

Read Full Article

VGI Health Technology Limited (NSX:VTL) June 2022 Quarterly Update

🕔7/29/2022 8:57:00 AM

The Directors of VGI Health Technology Limited (NSX:VTL) are pleased to provide the following update for the quarter ending 30 June 2022.

Read Full Article

Nanollose Limited (ASX:NC6) Quarterly Activities Report

🕔7/27/2022 8:20:49 AM

Nanollose Limited (ASX:NC6) (FRA:N0L) a leading biomaterials company, focused on commercialising scalable technology to create fibres and fabrics with minimal environmental impact, is pleased to provide shareholders with an overview of its activities for the period ended 30 June 2022.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Clinical Study Begins Recruitment of Patients

🕔7/5/2022 9:29:00 AM

VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd, has commenced recruitment of patients for its Phase II clinical study in Non-Alcoholic Fatty Liver Disease/Non-Alcoholic SteatoHepatitis.

Read Full Article